Journal Mobile Options
Table of Contents
Vol. 21, No. 5-6, 2006
Issue release date: May 2006
Dement Geriatr Cogn Disord 2006;21:316–321

Cognitive Impairment Related to Apathy in Early Huntington’s Disease

Baudic S. · Maison P. · Dolbeau G. · Boissé M.-F. · Bartolomeo P. · Dalla Barba G. · Traykov L. · Bachoud-Lévi A.-C.
aINSERM/UPVM U421 and bCentre Hospitalier Universitaire Henri Mondor, Créteil, and cINSERM U610 and dENS/LSCP, Paris, France

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Objective: To investigate the relationships between cognitive impairment and apathy in patients with early Huntington’s disease (HD) and to further explore the influence of depression on the outcome of cognitive changes associated with apathy. Methods: We included 36 early HD patients, among them 20 were apathetic (HDA) and 16 were not (HDnA). The two groups were matched by age, education and severity of disease. Cognitive functions were evaluated by a comprehensive neuropsychological battery that measures memory, attention, executive function, language and visuospatial abilities. Results: The HDA patients had significantly lower scores on memory, attention and executive function tests when compared with the HDnA patients (p values <0.05). We compared the performance of patients with (50%) and without depression on cognitive tasks and showed that depression per se did not influence performance. Finally, the results demonstrate that interactions between apathy and motor disturbance have a significant effect on cognitive impairment in HD. Discussion: The presence of apathy is associated with more severe deficits of attention, executive function and episodic memory in early HD patients. Furthermore, the findings suggest that depression has little or no effect on cognitive deficits. Finally, apathy increased in parallel with both motor and cognitive dysfunction.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Marin RS: Apathy: a neuropsychiatric syndrome. J Neuropsychiatry Clin Neurosci 1991;3:243–254.
  2. Marin RS, Firinciogullari S, Biedrzycki RC: The sources of convergence between measures of apathy and depression. J Affect Disord 1993;28:117–124.
  3. Kuzis G, Sabe L, Tiberti C, Dorrego F, Starkstein SE: Neuropsychological correlates of apathy and depression in patients with dementia. Neurology 1999;52:1403–1407.
  4. Pluck G, Brown R: Apathy in Parkinson’s disease. J Neurol Neurosurg Psychiatry 2002;73:636–642.
  5. Andersson S, Bergedalen A: Cognitive correlates of apathy in traumatic brain injury. Neuropsychiatry Neuropsychol Behav Neurol 2002;15:184–191.
  6. Paulsen J, Ready R, Hamilton J, Mega M, Cummings J: Neuropsychiatric aspects of Huntington’s disease. J Neurol Neurosurg Psychiatry 2001;71:310–314.
  7. Levy LM, Cummings JL, Fairbanks LA, Masterman D, Miller BL, Craig AH, Paulsen JS, Litvan I: Apathy is not depression. J Neuropsychiatry Clin Neurosci 1998;10:314–319.
  8. Craufurd D, Thompson J, Snowden J: Behavioral changes in Huntington’s disease. Neuropsychiatry Neuropsychol Behav Neurol 2001;14:219–226.
  9. Thompson J, Snowden J, Craufurd D, Neary D: Behavior in Huntington’s disease: dissociation cognition-based and mood-based changes. J Neuropsychiatry Clin Neurosci 2002;14:37–43.
  10. Nehl C, Ready R, Hamilton J, Paulsen J: Effects of depression on working memory in presymptomatic Huntington’s disease. J Neuropsychiatry Clin Neurosci 2001;13:342–346.
  11. Norman S, Troster A, Fields J, Brooks R: Effects of depression and Parkinson’s disease on cognitive functioning. J Neuropsychiatry Clin Neurosci 2002;14:31–36.
  12. Shoulson I: Huntington disease: functional capacities in patients treated with neuroleptic and antidepressant drugs. Neurology 1981;31:1333–1335.
  13. Bruland O, Almqvist E, Goldberg Y, Boman H, Hayden M, Knappskog P: Accurate determination of the number of CAG repeats in the Huntington disease gene using a sequence-specific internal DNA standard. Clin Genet 1999;55:198–202.
  14. Burns A, Folstein S, Brandt J, Folstein M: Clinical assessment of irritability, aggression, and apathy in Huntington’s disease and Alzheimer’s disease. J Nerv Ment Dis 1990;178:20–26.
  15. Caine ED, Shoulson I: Psychiatric syndromes in Huntington’s disease. Am J Psychiatry 1983;140:728–733.
  16. Bachoud-Levi AC, Maison P, Bartolomeo P, Boisse MF, Dalla Barba G, Ergis AM, Baudic S, Degos JD, Cesaro P, Peschanski M: Retest effects and cognitive decline in longitudinal follow-up of patients with early HD. Neurology 2001;56:1052–1058.
  17. Quinn N, Brown R, Craufurd D, Goldman S, Hodges J, Kieburtz K, Lindvall O, MacMillan J, Roos R: Core Assessment Program for Intracerebral Transplantation in Huntington’s Disease (CAPIT-HD). Mov Disord 1996;11:143–150.
  18. Huntington’s Disease Study Group: Unified Huntington’s disease rating scale: reliability and consistency. Mov Disord 1996;11:136–142.
  19. Mayeux R, Stern Y, Sano M: Clinical and biochemical correlates of bradyphrenia in Parkinson’s disease. Neurology 1987;37:1130–1134.
  20. Lundervold A, Reinvang I, Lundervold A: Characteristic patterns of verbal memory function in patients with Huntington’s disease. Scand J Psychol 1994;35:38–47.
  21. Starkstein S, Mayberg H, Preziosi T, Andrezejewski M, Leiguarda R, Robinson R: Reliability, validity, and clinical correlates of apathy in Parkinson’s disease. J Neuropsychiatry Clin Neurosci 1992;4:134–139.
  22. McPherson S, Fairbanks L, Tiken S, Cummings J, Back-Madruga C: Apathy and executive function in Alzheimer’s disease. J Int Neuropsychol Soc 2002;8:373–381.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50